Inglês · Medicine without frontiers: Lives on the Edge: Time to Align…
Nesta questão
Enunciado
INSTRUCTIONS: Read the following text carefully and then choose the correct alternatives that answer the questions or complete the statements placed after it.
Medicine without frontiers: Lives on the Edge: Time to Align Medical Research and Development with People’s Health Needs
Available at: <http://www.msf.ca/en/donate-now>.
EXECUTIVE SUMMARY
Every day, Médecins Sans Frontières (MSF) staff confront significant gaps in the availability of medical tools to address the health needs of the people we aim to care for, in crisis-affected communities in more than 60 countries.
These gaps – which have persisted for as long as MSF has been in operation – contribute to preventable deaths and exacerbate ongoing humanitarian and medical crises.
Filling these gaps with effective, affordable vaccines, diagnostics and treatments that can be used in a range of contexts, including under-resourced and unstable places, could save innumerable lives. In this report, MSF illustrates how our staff and patients around the world are impacted by the way biomedical research and development is predominantly conducted today.
The report also looks at a broad range of policies aimed at changing this dynamic by incentivising the development of medical tools that truly respond to patient and public health needs, and ensuring they are made broadly accessible.
There are at least four harmful consequences of the way medical research and development is conducted today:
Failing to deliver for diseases that aren’t sufficiently lucrative.
The current biomedical innovation system is overwhelmingly driven by financial interests; pharmaceutical companies develop drugs based on the likely return that a product will offer through sales. The result is a lack of investment in drugs, diagnostics and vaccines to meet the needs of people who can’t afford to pay high prices, or who don’t constitute a sizeable or lucrative market. MSF experiences the consequences of this acutely: for example, with the lack of treatments or vaccines for Ebola virus during the 2014 pandemic; the inadequate or non-existent treatments for neglected diseases such as Chagas disease and visceral leishmaniosis; and the long, toxic and insufficiently effective treatments routinely used to treat drug-resistant tuberculosis.
Failing to prioritise according to public health needs.
With current incentive mechanisms, the biomedical innovation system concentrates investment on products that will sell well, and not necessarily on existing public health priorities. For example, the urgent need for new antibiotics has been widely documented, but governments have been slow to put in place the right incentive mechanisms to encourage development of new antibiotics, and this medical priority remains unanswered by pharmaceutical companies. MSF is witnessing first-hand the emergence of antibiotic resistance in our projects, including in child nutritional centres in Niger and in adult trauma patients in Syria and Jordan. Industry is abandoning work in other areas critical to public health, including anti-infectives such as tuberculosis medicines. Governments have failed to implement the necessary incentive mechanisms to ensure that therapeutic importance – and not solely financial reward – influences product development prioritisation.
Failing to deliver affordable products.
High prices are inherently linked to a reliance on patent monopolies as the way to finance biomedical R&D. Patents and other forms of intellectual property rights give companies exclusive rights to make and sell a product with no fear of competition, leaving producers largely free to charge what they please.
Many people, medical providers and governments face unsustainably high prices for medicines, such as for the hepatitis C drug sofosbuvir that costs up to US$ 1,000 per pill. MSF is working to scale up immunisation against pneumonia, the leading cause of death for young children worldwide, but the high price of the vaccine has been a barrier. As a treatment provider supporting more than 230,000 people on lifelong antiretroviral (ARV) treatment, MSF needs access to salvage regimens that contain newer HIV medicines such as raltegravir and etravirine, but they are priced at least 18 times higher than first-line treatment.
Failing to use scientific and financial resources efficiently and effectively.
Existing incentive mechanisms hamper collaboration among researchers. Exclusive intellectual property rights encourage scientists to work in isolation from, and in competition with, one another. Follow-on innovation is also restricted; for example, creating a multidrug regimen or a combination pill can’t easily happen if the relevant patents are owned by competing companies.
This siloed approach has blocked the development of new therapies against tuberculosis that MSF has long called for. Secrecy around clinical trials and safety data can also lead to adverse patient outcomes with tremendous financial, social and health consequences.
Available at: <http://www.msf.ca/en/donate-now>. Accessed on: Sept. 21st, 2016 (Edited).
One of the great priorities in drugs for the public health lies in the production of:
Ideia central: identificar uma prioridade explicitamente nomeada.
O texto destaca a necessidade urgente de novos antibióticos, apesar da lentidão dos incentivos para desenvolvê-los. As outras opções trocam medicamentos por vírus, pela própria doença ou por uma característica indesejada de tratamento.
Resposta: A. Procure a expressão “urgent need for new antibiotics”.
Estude com a MMI
Matemática e Física com direção.
Conheça os cursos com Ramon Siqueira e os materiais para a sua preparação.